PT-141, also known by its chemical designation bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) developed through structural modification of the earlier compound melanotan II. Its primary area of scientific interest lies in its interactions with melanocortin receptors, specifically MC3R and MC4R, which are widely distributed throughout the central nervous system and peripheral tissues. For UK researchers exploring the melanocortin system, PT-141 bremelanotide research represents a well-documented avenue for understanding receptor-mediated signalling pathways.
Molecular Background and Receptor Pharmacology
The melanocortin system comprises five G protein-coupled receptor subtypes (MC1R through MC5R), each with distinct tissue expression profiles and downstream signalling consequences. PT-141 demonstrates selective binding affinity at MC3R and MC4R, distinguishing it from broader-acting melanocortin ligands. This selectivity has made it a useful tool in preclinical models designed to dissect the functional roles of these receptor subtypes in hypothalamic and limbic circuits.
Unlike many peptide-based research compounds, PT-141 exhibits notable resistance to enzymatic degradation due to its cyclic structure, providing researchers with extended in vitro and in vivo stability. Researchers sourcing compounds for receptor binding studies can explore the full range of available melanocortin compounds to support experimental design across this receptor family.
Documented Research and Preclinical Findings
Preclinical investigation into PT-141 has produced a substantial body of literature focused on central nervous system activity. Early studies identified MC4R activation in the hypothalamus and mesolimbic regions as a key mechanistic component of the compound’s observed effects in animal models. Molinoff et al. (2003) provided foundational characterisation of bremelanotide’s receptor activity and its differentiation from peripheral vascular peptides, offering a useful reference point for researchers designing binding assays.
Subsequent investigations have expanded the scope of PT-141 research to examine its interactions with dopaminergic pathways. The convergence of melanocortin and dopamine signalling in the nucleus accumbens and medial preoptic area has been a recurring focus, with researchers examining how MC4R agonism modulates reward-related circuitry. Pfaus et al. (2004) explored these neurochemical intersections in rodent models, providing mechanistic context for observed behavioural outcomes in controlled laboratory settings.
For researchers building a broader understanding of neuropeptide signalling, additional resources and compound profiles are available through the peptide encyclopaedia, which covers structural classifications and receptor interaction data across multiple peptide families.
Research Applications in Melanocortin System Studies
Within the context of laboratory research, PT-141 bremelanotide is utilised across several investigative areas relevant to the melanocortin field:
- Receptor binding and selectivity assays targeting MC3R and MC4R subtypes
- Examination of hypothalamic neuropeptide circuitry in animal models
- Investigation of melanocortin-dopamine pathway interactions in limbic structures
- Comparative pharmacology studies alongside other cyclic melanocortin analogues
- Signal transduction research involving cAMP-mediated downstream cascades
These applications position PT-141 as a structurally and pharmacologically distinct research tool within a broader programme of melanocortin receptor investigation. Researchers interested in parallel neurological pathway work may also find relevant compounds in the cognitive and neurological compounds category.
Structural Stability and Experimental Considerations
The cyclic heptapeptide architecture of PT-141 confers significant proteolytic resistance compared to linear melanocortin peptides, making it particularly suitable for extended in vitro assay protocols. Researchers should account for its increased receptor residence time relative to endogenous α-MSH when designing dose-response curves or displacement assays. Lyophilised storage at -20°C under desiccated conditions is standard practice for preserving compound integrity across extended research programmes. Diamond et al. (2004) documented pharmacokinetic parameters relevant to experimental dosing considerations in preclinical contexts.
Key Takeaways
- PT-141 bremelanotide is a cyclic heptapeptide analogue of α-MSH with selective affinity for MC3R and MC4R subtypes
- Its cyclic structure provides enhanced enzymatic stability compared to linear melanocortin peptides
- Preclinical research has focused predominantly on hypothalamic and mesolimbic signalling pathways
- It is classified as a research compound only and is not intended for human use
- UK researchers can source verified PT-141 alongside other melanocortin compounds through dedicated research suppliers
Frequently Asked Questions
What receptors does PT-141 bremelanotide bind to?
PT-141 primarily binds to melanocortin receptor subtypes MC3R and MC4R. This selectivity differentiates it from earlier analogues such as melanotan II and makes it a useful tool for subtype-specific receptor research.
Is PT-141 suitable for in vitro receptor binding studies?
Yes, its structural stability and well-characterised receptor affinity profile make it appropriate for in vitro binding assays. Researchers should consult peer-reviewed literature for validated assay conditions before use.
Where can UK researchers access further reading on melanocortin peptides?
The research hub contains ongoing editorial content covering peptide pharmacology, receptor systems, and experimental methodology relevant to UK-based research programmes.
Is PT-141 approved for human use in the UK?
PT-141 bremelanotide is supplied strictly as a laboratory research compound. It is not approved or intended for human consumption in the UK, and all use must remain within controlled research settings.
This content is intended for qualified researchers and scientific professionals only. All compounds are for laboratory research use only. Not for human consumption.
